Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Minuto

Showing results (21-30 of 31) with videos related to

Pageof 4
Sort By:
The Journal of Clinical Endocrinology and Metabolism|September 6, 2007
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinomaCristiana Lupi, Riccardo Giannini, Clara Ugolini, et al.
Molecular and Cellular Endocrinology|November 22, 2011
Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytesAlessandro Antonelli, Silvia Martina Ferrari, Silvia Frascerra, et al.
Clinical Endocrinology|September 13, 2008
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cellsAlessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Low-Dose Versus Standard-Dose Radioiodine Therapy in Differentiated Thyroid Cancer: Focus on Tolerability in a Retrospective EvaluationLaura Musso, Cristina Maltese, Giulio Beretta, et al.
Endocrine-Related Cancer|September 17, 2009
Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonistsAlessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, et al.
Updates in Surgery|April 15, 2024
Management of surgical diseases of Primary Hyperparathyroidism: indications of the United Italian Society of Endocrine Surgery (SIUEC)Paolo Del Rio, Marco Boniardi, Loredana De Pasquale, et al.
Future Oncology (London, England)|August 7, 2019
Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinomaStefano Gay, Eleonora Monti, Chiara Trambaiolo Antonelli, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2010
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancerAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Medicine|April 9, 2016
Can Total Thyroidectomy Be Safely Performed by Residents?: A Comparative Retrospective Multicenter StudyAngela Gurrado, Rocco Bellantone, Giuseppe Cavallaro, et al.
Pageof 4

Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
The Journal of Clinical Endocrinology and Metabolism|September 6, 2007
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinomaCristiana Lupi, Riccardo Giannini, Clara Ugolini, et al.
Molecular and Cellular Endocrinology|November 22, 2011
Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytesAlessandro Antonelli, Silvia Martina Ferrari, Silvia Frascerra, et al.
Clinical Endocrinology|September 13, 2008
Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cellsAlessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, et al.
Pharmaceuticals (Basel, Switzerland)|April 26, 2025
Low-Dose Versus Standard-Dose Radioiodine Therapy in Differentiated Thyroid Cancer: Focus on Tolerability in a Retrospective EvaluationLaura Musso, Cristina Maltese, Giulio Beretta, et al.
Endocrine-Related Cancer|September 17, 2009
Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonistsAlessandro Antonelli, Silvia Martina Ferrari, Poupak Fallahi, et al.
Updates in Surgery|April 15, 2024
Management of surgical diseases of Primary Hyperparathyroidism: indications of the United Italian Society of Endocrine Surgery (SIUEC)Paolo Del Rio, Marco Boniardi, Loredana De Pasquale, et al.
Future Oncology (London, England)|August 7, 2019
Case report: lenvatinib in neoadjuvant setting in a patient affected by invasive poorly differentiated thyroid carcinomaStefano Gay, Eleonora Monti, Chiara Trambaiolo Antonelli, et al.
The Journal of Clinical Endocrinology and Metabolism|December 15, 2010
Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancerAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
The Journal of Clinical Endocrinology and Metabolism|January 27, 2012
CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivoAlessandro Antonelli, Guido Bocci, Concettina La Motta, et al.
Medicine|April 9, 2016
Can Total Thyroidectomy Be Safely Performed by Residents?: A Comparative Retrospective Multicenter StudyAngela Gurrado, Rocco Bellantone, Giuseppe Cavallaro, et al.
Pageof 4